Rapid hereditary breast cancer

Treat breast cancer patients sooner

When it comes to breast cancer treatment, recent studies have shown that a longer time to treatment completion has a negative impact on the overall outcome and survival of patients.1,2

Delivering results in 10–14 days, our rapid breast cancer treatment decision panel is designed to detect 11 genes linked to lifetime breast cancer risk, in alignment with guidelines established by the National Comprehensive Cancer Network (NCCN). Of the 11 genes our panel detects, seven are considered high risk based on NCCN guidelines for breast cancer risk management and treatment. Our panel also includes four moderate-risk genes, allowing clinicians to cast a broader net and reduce the need for subsequent reflex testing.

Rapid hereditary breast cancer test menu

Rapid hereditary breast cancer

Key testing


  • Includes detection of seven high-risk genes (BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, and TP53), which carry a 40%–60% lifetime likelihood of the presence of cancer, and four moderate risk genes (ATM, CHEK2, RAD51C, and RAD51D), which indicate a 20%–40% lifetime likelihood of cancer occurrence.
  • Delivers results in 10–14 days, providing clinicians and patients with information to quickly guide treatment decisions.
  • Carefully designed to balance clinical utility diagnostic yields and future-proofing that will generate the most impactful genetic testing results for patients with breast cancer.


  1. Pratt D, Burneikis T, Tu C, Grobmyer S. Time to completion of breast cancer treatment and survival. Ann Surg Oncol. 2021;28(13):8600-8608. doi:10.1245/s10434-021-10116-9.
  2. Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States [published correction appears in JAMA Oncol. 2016 Sep 1;2(9):1244]. JAMA Oncol. 2016;2(3):330-339. doi:10.1001/jamaoncol.2015.4508.

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.